Novel Drug Targeting Leukemia Cells Enters Clinical Trial

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. … Read the full story from the UC San Diego Newsroom


A team led by Dr. Thomas Kipps developed the new antibody, known as cirmtuzumab or UC-961. The work was conducted and supported by a California Institute for Regenerative Medicine HALT grant to co-principal investigators Dennis Carson, MD, and Catriona Jamieson, PhD, MD.

Dr. Thomas Kipps

Catriona H. M. Jamieson, MD, PhDDennis Carson, MD

L to R: Drs. Kipps, Jamieson and Carson.